Telomir Pharmaceuticals, Inc. (TELO) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US87975F1049

Price
0.96 USD
Market cap
66.31 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-176.10 %
Return on assets (ROA)
-141.84 %

Telomir Pharmaceuticals, Inc. financials

Fiscal year20242025
EBIT-12.19 m USD-10.54 m USD
Net income-16.53 m USD-10.41 m USD
Diluted EPS – continuing operations0.56 USD-0.33 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.